

F. No. ND/MA/25/000141
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-11 0002

To

**M/s Sun Pharmaceutical Industries Limited,
Tandalja, Vadodara – 390012, Gujarat.**

Subject: Grant of permission to conduct Phase-III Clinical trial of drug Suvorexant Tablets 10mg, 15mg and 20 mg vide protocol titled “A Prospective, Multicenter, Randomized, Assessor blind, Parallel-group, Active-Controlled, Phase III Comparative Study to Evaluate the Efficacy and Safety of Suvorexant Tablets in Comparison to Lemborexant Tablets in Patients with Insomnia.” Protocol Number: ICR/25/017 Protocol Version No: 1.0, dated 22-Aug-2025 -regarding.

Sir,

With reference to your application no. **ND/CT21/FF/2025/51942** dated **13.09.2025**; please find enclosed herewith the permission in **Form CT-06, vide No. CT/ND/40/2025** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,
RAJEEV SINGH
RAGHUVANSHI
Digitally signed by RAJEEV
SINGH RAGHUVANSHI
Date: 2025.12.29 10:14:46
+05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the

Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with

the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06*(See rules 22, 25, 26, 29 and 30)***PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG****CT NO. CT/ND/40/2025**

The Central Licensing Authority hereby permits, **M/s Sun Pharmaceutical Industries Limited, Tandalja, Vadodara – 390012, Gujarat. Tel.: (91-265) 661 5500 Fax : (91-265) 235 4897, Email ID: IRA@sunpharma.com** to conduct clinical trial of the new drug as per **Protocol Number: ICR/25/017, Version No.: 1.0 dated 22nd August 2025** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:	Suvorexant Tablets 10mg, 15mg and 20 mg
Therapeutic class:	Orexin receptor antagonist
Dosage form:	Tablets
Composition:	<p>For 10 mg: Each film coated tablet contains: Suvorexant 10 mg Excipients q.s. Colours: Titanium Dioxide IP, Lake of Indigo Carmine and Ferric Oxide (Yellow) USP-NF</p> <p>For 15 mg: Each film coated tablet contains: Suvorexant 15 mg Excipients q.s. Colours: Titanium Dioxide IP</p> <p>For 20 mg: Each film coated tablet contains: Suvorexant 20 mg Excipients q.s. Colours: Titanium Dioxide IP</p>
Indications:	Indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Details of clinical trial sites-	
Sr. No.	Name of Principal Investigator & Trial Sites
Ethics Committee Name/ Registration Number	
1.	Dr. K. Mrudhula Gandhi Hospital, Department of Neurology, Secunderabad, Telangana
	Institutional Ethics Committee, Gandhi medical college and hospital Registration number: ECR/180/Inst/AP/2013/RR-24
2	Dr. Richa Giri
	Ethics Committee GSVM medical college.

	G.S.V.M. Medical College, Postgraduate Department of Medicine, Kanpur, Uttar Pradesh.	Registration number: ECR/680/Inst/UP/2014/RR-20
3	Dr. Kausik Bhar IPGMER & SSKM Hospital, Department of Medicine, Kolkata, West Bengal	IPGMEandR Research Oversight Committee IPGME&R SSKM hospital Registration number: ECR/35/Inst/WB/2013/RR-24
4	Dr. Asish Mukhopadhyay Nil Ratan Sircar Medical College & Hospital, Department of Psychiatry, Kolkata, West Bengal	Ethics Committee, N.R.S. Medical College, N.R.S. Medical College & Hospital Registration number: ECR/609/Inst/WB/2014/RR-25
5	Dr. G. Sree Ranga Lakshmi Osmania General Hospital, Department of Neurology, Hyderabad, Telangana	Institutional Ethics Committee - Osmania Medical College. Registration number: ECR/300/Inst/AP/2013/RR-24
6	Dr. Anurag Verma Motilal Nehru Medical College, Department of Psychiatry, Prayagraj, Uttar Pradesh	Institutional Ethics Committee, MLN Medical College Registration number: ECR/922/Inst/UP/2017/RR-22
7	Dr. Sunil Kumar Mahavar SMS Hospital, Department of Medicine, Dhanvantari OPD Block, Jaipur, Rajasthan	Ethics Committee, S.M.S. Medical College and attached Hospital Registration number: ECR/26/Inst/RJ/2013/RR-24
8	Dr. Naveen Korivi St. Ann 's General & Cancer Hospital, Room no. 3, Ground floor, Department of Neurolog, Fathimanagar, Kazipet, Warangal, Telangana.	St. Anns Institutional Ethics Committee Registration number: ECR/1297/Inst/TG/2019/RR-24
9	Dr. Parikh Minakshi Nimesh B.J.Medical College and Civil Hospital, Department of Medicine, Asarwa, Ahmedabad, Gujarat.	Institutional Ethics Committee, B.J.Medical College and Civil Hospital Registration number: ECR/72/Inst/GJ/2013/RR-24
10	Dr. Kusumgar Rohan Deepakkumar Medinlik Hospital, Ahmedabad, Gujarat.	Medilink Ethics Committee; Medilink Hospital Research Centre, Ahmedabad Registration number: ECR/344/Inst/GJ/2013/RR-24
11	Dr. Patojoshi Amrit Hi Tech Medical College & Hospital, Department of Psychiatry, Bhubaneswar, Odisha.	Institutional Ethics Committee, Hi-Tech MCH. Registration number: ECR/273/Inst/OR/2013/RR-20
12	Dr. Gupta Parveen Marengo Asia Hospitals, Marengo Asia International Institute of Neuro & Spine (MAIINS), Gurugram.	EC of North East Healthcare Pvt Ltd. Registration number: ECR/2048/Inst/HR/2025
13	Dr. Anshu Rohtagi Sir Ganga Ram Hospital, Department of Neurology, Rajinder Nagar New Delhi.	Sir Ganga Ram Hospital Ethics Committee. Registration number: ECR/20/Inst/DL/2013/RR-24
14	Dr. Hrishikesh Kuma	IEC, Institute of Neurosciences.. Registration number: ECR/185/Inst/WB/2013/RR-24

	Institute of Neuroscience, Department of Neurology, Kolkata, West Bengal..	
15	Dr. Chalam Das. V. Sunrise Hospital, Department of Psychiatry, Kochi, Kerala.	Institutional Ethics Committee Lakshmi Nursing Home. Registration number: ECR/1781/Inst/KL/2023
16	Dr. Bhalchandra P. Kalmegh Pulse Multispeciality Hospital, Mumbai – Bangalore, Highway, Narhe, Pune..	Ethics Committee of Pulse Multispecialty Hospital. Registration number: ECR/1339/Inst/MH/2020/RR-25
17	Dr. Patil Bhushan Subhash Asian Institute of Medical Sciences, Dombivali, East..	Suraksha Ethics Committee Registration number: ECR/644/Inst/MH/2014/RR-20
18	Dr. Dey Snehanshu KIDS Hospital, Department of Psychiatry, Bhubaneswar Khordha, Odisha.	KIDS Ethics Committee Registration number: ECR/1132/Inst/OD/2018/RR-22

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH Digitally signed by RAJEEV
SINGH RAGHUVANSHI
RAGHUVANSHI Date: 2025.12.29 10:15:09
+05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority
Stamp

New Delhi